0001104659-14-017515.txt : 20140307 0001104659-14-017515.hdr.sgml : 20140307 20140307162400 ACCESSION NUMBER: 0001104659-14-017515 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140304 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20140307 DATE AS OF CHANGE: 20140307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 14677583 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 100 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 100 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 8-K/A 1 a14-7672_18ka.htm 8-K/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

(Amendment No. 1)

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 4, 2014

 

PACIRA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-35060

 

51-0619477

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

5 Sylvan Way, Suite 100, Parsippany, New Jersey 07054

(Address of principal executive offices) (Zip Code)

 

(973) 254-3560

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

EXPLANATORY NOTE

 

This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed by Pacira Pharmaceuticals, Inc. on March 6, 2014 (the “Original 8-K”), which disclosed the appointment of a new director. This amendment is being filed solely to correct certain biographical information of the new director provided in the Original 8-K.

 

Item 5.02.                                        Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 4, 2014, the Board of Directors (the “Board”) of Pacira Pharmaceuticals, Inc. (the “Company”) appointed Dr. Yvonne Greenstreet to serve as a Class III director.

 

Dr. Greenstreet has over 20 years of global experience in the pharmaceutical industry.  She most recently served as the Senior Vice President and Head of Medicines Development at Pfizer, Inc., a multinational pharmaceutical company based in New York. Prior to joining Pfizer, Dr. Greenstreet worked for 18 years at GlaxoSmithKline plc (“GSK”), a multinational pharmaceutical, biologics, vaccines and consumer healthcare company based in London, where she served in various positions, most recently as Senior Vice President and Chief of Strategy for Research and Development and as a member of GSK’s corporate executive investment committee.  Dr. Greenstreet currently serves on the Advisory Board of the Bill and Melinda Gates Foundation. She trained as a physician and earned her medical degree from Leeds University in the United Kingdom and her MBA from INSEAD, France.

 

Dr. Greenstreet has been appointed to the Compensation Committee of the Board.  As compensation for her service on the Board and the Compensation Committee, Dr. Greenstreet will receive the Company’s standard compensation for non-employee directors.  There are no understandings or arrangements between Dr. Greenstreet and any other person pursuant to which she was selected as a director.  The Board considered the independence of Dr. Greenstreet under the Nasdaq listing standards and concluded that she is independent under the applicable Nasdaq standards.

 

2


 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Pacira Pharmaceuticals, Inc.

 

 

 

Date: March 7, 2014

By:

/s/ James Scibetta

 

 

James Scibetta

 

 

Chief Financial Officer

 

3